Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Titel:
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Auteur:
Jänne, Pasi A Shaw, Alice T Pereira, José Rodrigues Jeannin, Gaëlle Vansteenkiste, Johan Barrios, Carlos Franke, Fabio Andre Grinsted, Lynda Zazulina, Victoria Smith, Paul Smith, Ian Crinò, Lucio